Sikander Ailawadhi, MD

The panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.

A panel of oncology experts discuss recent advancements surrounding novel therapies for CLL, exploring their potential impact on future treatment paradigms.

Sameer A Parikh, MD, leads an expert discussion regarding emerging resistance data and its potential impact on treatment sequencing.

Sikander Ailawadhi, MD, review real-world data findings recently presented at ASH 2023, highlighting their potential implications on the treatment landscape.

A panel of oncology experts review meta-analysis data evaluating bleeding risk with covalent BTKis, discuss the impact of these data on treatment decision making, and explore strategies in managing BTKi-related bleeding risk.

Sikander Ailawadhi, MD, offers expert insight into managing the risk of atrial fibrillation in CLL patients receiving BTKis.

Amber Koehler, PA-C, provides expert perspective on addressing hypertension risk in CLL patients undergoing treatment with BTK inhibitors.

A panel of oncology experts offer insights into key consideration factors for BTKi selection for CLL in the relapsed and refractory setting, exploring the impact of emerging MAIC data on treatment decision making.

A panel of oncology experts review recently presented data updates from ALPINE and ELEVATE-RR, discussing the potential impact of these findings on the clinical practice setting.

A panel of oncology experts share their general approach in navigating treatment selection for patients with R/R CLL, highlighting key factors to consider in making treatment decisions.

Expert faculty highlight key updates from trials evaluating combination therapy approaches using venetoclax plus a BTKi in the frontline setting.

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient selection.

Expert faculty discuss consideration factors in guiding frontline treatment selection with BTKis in CLL.

A panel of oncology experts explore recent updates from SEQUOIA and ELEVATE-RR, discussing the potential impact of these findings on the clinical practice setting.

A panel of oncology experts discuss the role of 1L combination therapy using obinutuzumab plus a BTKi, highlighting key consideration factors for patient selection.

In this Cancer Network Around the Practice program, Mazie Tsang, MD offers an overview of the current landscape surrounding frontline therapy in CLL.